Our Pick: MEDVi
Check price →MEDVi Review: GLP-1 Weight Loss Program Cost & Honest Verdict
A clear-eyed look at MEDVi's physician-supervised GLP-1 program — what the membership actually includes, how its pricing compares, and where it falls short.
By The GLP-1 Samples Desk · 11 min read · 2026-06-14
Find your match.
Answer two quick questions — we'll point you to the GLP-1 provider that fits and what it actually costs.
MEDVi is a telehealth company that connects adults with licensed clinicians who can evaluate whether a GLP-1 medication is appropriate for weight management, and — when clinically indicated and legally permitted — write a prescription. Like most of the newer GLP-1 telehealth services, MEDVi has built its program around compounded semaglutide and compounded tirzepatide, the lower-cost alternatives to branded Wegovy and Zepbound. That single fact shapes almost everything worth knowing about the service, including its price, its risks, and who it makes sense for.
We reviewed MEDVi the way we review every provider on this site: by reading its own public-facing terms, comparing its advertised structure against competitors, and separating what we could independently confirm from what we could not. We do not accept payment for placement, and a provider being on our approved list does not buy it a better verdict. This review is educational and is not medical advice.
The short version: MEDVi is a credible, physician-supervised option with transparent-ish flat pricing and bundled coaching, but it competes in an extremely crowded field where the differences between services are smaller than the marketing suggests. The most important caveat is one that applies to nearly all of these programs — compounded GLP-1 medications are not FDA-approved, and that is a meaningful distinction a reader should understand before choosing any compounded provider.
The short version
- MEDVi is a telehealth platform: it facilitates a consultation with a licensed provider and, if appropriate, a prescription. It does not itself manufacture, approve, or guarantee any medication. Verify all current pricing and inclusions directly at medvi.com before enrolling.
- MEDVi's program is built primarily around compounded semaglutide and compounded tirzepatide. Compounded drugs are NOT FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality — this applies to MEDVi and to most competing GLP-1 telehealth services.
- Pricing is positioned as a flat monthly membership that bundles the clinician visit, ongoing supervision, and the medication into one figure, rather than charging separately for the visit. MEDVi advertises no insurance and no hidden visit fees, but exact dollar amounts change frequently and must be confirmed at the source.
- The clinical efficacy of the underlying GLP-1 molecules (semaglutide, tirzepatide) is established in published trials of the BRANDED FDA-approved versions — not for any specific compounded formulation. No telehealth program, MEDVi included, can promise you a specific result.
- MEDVi is a reasonable pick for a price-sensitive adult who wants compounded GLP-1 access with bundled support and is comfortable with the compounding trade-off. Anyone who wants the FDA-approved branded drug, or whose insurance might cover it, should weigh that path first.
| Provider | Core medication type | Pricing model | Insurance | Notable trait |
|---|---|---|---|---|
| MEDVi | Compounded semaglutide / tirzepatide | Flat monthly membership, med bundled | Cash-pay | Bundled price + included supervision |
| Henry Meds | Compounded semaglutide / tirzepatide | Monthly membership | Cash-pay | Well-known early compounded-GLP-1 brand |
| Ivim Health | Compounded + branded options | Membership + med | Cash-pay; some insurance for visits | Lab-forward, coaching emphasis |
| Eden | Compounded semaglutide / tirzepatide | Per-month, dose-tiered | Cash-pay | Transparent dose-based pricing pages |
| LillyDirect | Branded (FDA-approved) Zepbound / Mounjaro | Manufacturer-direct cash pricing | Cash; some insurance pathways | Maker-direct, FDA-approved drug |
| NovoCare | Branded (FDA-approved) Wegovy / Ozempic | Manufacturer cash program | Cash; insurance pathways | Maker-direct, FDA-approved drug |
How MEDVi stacks up against other approved GLP-1 telehealth providers we cover. All figures are provider-attributed and change frequently — verify current pricing and inclusions at each provider's site. Compounded medications referenced below are NOT FDA-approved.
Find your match
30-sec finder
Question 1 of 6
What brings you here today?
01 · Price-sensitive adults who want bundled compounded GLP-1 access with included supervision
Reviewed ProviderMEDVi GLP-1 Weight Management Program
A physician-supervised, compounded-GLP-1 telehealth program with flat bundled pricing — solid value, but it lives or dies on the compounding trade-off shared across the category.
What we verified: What we could verify: MEDVi publicly presents itself as a telehealth service that arranges consultations with licensed clinicians for GLP-1 weight management, built around compounded semaglutide and compounded tirzepatide, with a flat-membership pricing model that bundles the medication and clinical oversight. What we could NOT independently verify: the specific 503A/503B compounding pharmacies used, current exact dollar pricing (it changes), real-world shipping timelines, and the credentials of individual prescribing clinicians. We did not lab-test any medication and make no representation about the contents of any product shipped. Confirm all specifics directly with MEDVi.
What MEDVi actually is
It helps to be precise about the product, because the marketing in this category blurs it. MEDVi is not a pharmacy and not a drug manufacturer. It is a telehealth platform: you complete an intake, a licensed clinician reviews your information (and, in many states, conducts a synchronous or asynchronous visit), and if a GLP-1 medication is determined to be appropriate and you have no disqualifying contraindications, a prescription can be issued and routed to a partner pharmacy that fills it. MEDVi's role is the connective tissue — intake, clinician access, ongoing check-ins, and logistics.
The medication at the center of the program is, in the typical case, compounded semaglutide or compounded tirzepatide — the same active molecules as Wegovy/Ozempic (semaglutide) and Zepbound/Mounjaro (tirzepatide), but prepared by a compounding pharmacy rather than purchased as the branded, FDA-approved product. This is the single most important thing to understand, and we return to it below.
The membership and what's bundled
MEDVi's pricing pitch is a flat monthly membership. Rather than charging a separate consultation fee and then a separate medication cost, MEDVi advertises a single figure that is intended to cover the clinical visit, ongoing provider supervision, and the medication itself. The company markets this as not requiring insurance and as avoiding surprise per-visit charges. We did not find a basis to dispute the flat-bundle structure, but the exact dollar amount is the part you must verify yourself — it moves, and it can depend on the molecule (semaglutide vs. tirzepatide) and the dose tier.
Bundled coaching and messaging-based support are part of the pitch. In practice, "coaching" across this entire category ranges from genuinely useful structured programs to little more than a messaging inbox, so treat any provider's coaching claim — MEDVi's included — as something to confirm rather than assume.
The visit experience
The intake-to-prescription flow is the standard asynchronous telehealth pattern: a health questionnaire, medical history, often a requested weight/height for BMI, and screening questions for contraindications (personal or family history of medullary thyroid carcinoma or MEN 2, pancreatitis history, pregnancy, etc., which are standard GLP-1 screening items reflected on the FDA labels for the branded drugs). A licensed clinician reviews this before any prescription. The convenience is real; the trade-off, common to asynchronous telehealth, is that the depth of evaluation is lighter than an in-person workup with labs. Some buyers value a program that requires or offers lab work — that is worth asking MEDVi about directly.
The compounding question — read this part
Compounded GLP-1 medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients. Compounding is legal and long-standing, and it surged for GLP-1 drugs during the FDA-recognized shortages of semaglutide and tirzepatide. But as those shortages have resolved, the regulatory environment for mass-compounded GLP-1s has tightened, and the FDA has issued repeated cautions about compounded semaglutide products — including dosing errors and salt-form versions (semaglutide sodium/acetate) that differ from the approved active ingredient. None of this is unique to MEDVi; it is the defining risk of the compounded telehealth model, and any honest review has to put it front and center. If you want the molecule with the published trial evidence and FDA review behind it, that is the branded product, accessed through a different route.
What the evidence does and doesn't say
The efficacy data people cite for "GLP-1 weight loss" comes from trials of the FDA-approved branded drugs. In the STEP program, the manufacturer-sponsored trial of branded semaglutide 2.4 mg (Wegovy) reported a mean body-weight reduction of roughly 14.9% over 68 weeks versus about 2.4% with placebo (Wilding et al., NEJM, 2021). For tirzepatide (Zepbound), the SURMOUNT-1 trial reported mean reductions up to about 20.9% at the highest dose over 72 weeks (Jastreboff et al., NEJM, 2022). These are findings for the branded, FDA-approved formulations under trial conditions — they are not promises, they are not transferable claims about any compounded product, and individual results are determined by a clinician, your physiology, dose, and adherence. We cite them so you understand the molecules; we are not telling you what will happen to you.
- Model
- Telehealth platform (consult + prescription routing)
- Primary medications
- Compounded semaglutide; compounded tirzepatide
- FDA status of meds
- Compounded — NOT FDA-approved
- Pricing structure
- Flat monthly membership, medication bundled (verify at source)
- Insurance
- Marketed as cash-pay / no insurance required
- Clinical oversight
- Licensed clinicians; ongoing supervision included
- Eligibility
- Adults 18+, subject to clinician evaluation & contraindication screening
- Labs
- Confirm directly — varies
What we like
- Flat, bundled monthly pricing that folds the visit and medication into one figure (MEDVi-attributed)
- Cash-pay model removes insurance friction for those who can't or don't want to use it
- Physician-supervised with ongoing check-ins, not a one-and-done script
- Convenient fully-remote intake-to-prescription flow
- Includes coaching/support messaging as part of the membership
Worth noting
- Built on compounded semaglutide/tirzepatide, which are NOT FDA-approved
- Exact current pricing is hard to confirm without beginning enrollment
- Compounding pharmacies and individual prescriber credentials not independently verifiable by us
- Asynchronous evaluation is lighter than an in-person, lab-based assessment
- Doesn't meaningfully out-feature the strongest competitors in a saturated market
Who should buy it: Adults (18+) who have decided they want compounded GLP-1 access, want the visit and medication bundled into one predictable monthly price, don't have (or don't want to use) insurance for a branded drug, and understand and accept that compounded medications are not FDA-approved. It's a particularly reasonable pick for someone comparison-shopping on price who still wants included clinical supervision rather than a bare-bones script mill.
What we don't like: The program rests on compounded, non-FDA-approved medication — the category's core risk, not unique to MEDVi but unavoidable here. Exact pricing is hard to pin down without starting an intake, and bundled 'coaching' is vaguely defined. We also couldn't independently verify which compounding pharmacies are used or the credentials of individual prescribers, and the asynchronous model offers a lighter evaluation than a lab-based, in-person workup.
Bottom line: MEDVi is a legitimate, mid-tier-to-strong entry in the compounded-GLP-1 telehealth space. Its bundled flat pricing and included coaching are genuine conveniences, and its physician-supervised framing is appropriate. But it does not meaningfully out-feature the best competitors, and — like nearly all of them — it rests on compounded medication that is not FDA-approved. We rate it a qualified recommendation: a good fit for the right buyer who understands that trade-off, not a default choice for everyone.
Questions, answered
Is MEDVi legit?
MEDVi is a real telehealth company that connects adults with licensed clinicians for GLP-1 weight management and routes prescriptions to partner pharmacies when a clinician deems it appropriate. In that sense it is legitimate. The important nuance is that its program is built mainly around compounded semaglutide and tirzepatide, which are not FDA-approved. 'Legit company' and 'FDA-approved medication' are two different things — MEDVi is the former; its compounded medications are not the latter. Always verify current details at medvi.com.
How much does MEDVi cost?
MEDVi advertises a flat monthly membership that bundles the clinician visit, ongoing supervision, and the medication into one figure, with no insurance required. The exact dollar amount changes frequently and can vary by medication (semaglutide vs. tirzepatide) and dose tier, so we don't quote a fixed number — confirm the current price directly with MEDVi before enrolling. This is provider-attributed pricing.
Are MEDVi's GLP-1 medications FDA-approved?
No. Like most GLP-1 telehealth services, MEDVi's program centers on compounded semaglutide and compounded tirzepatide, which are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients. If you want the FDA-approved branded versions (Wegovy, Ozempic, Zepbound, Mounjaro), you'd pursue those through a different route, such as manufacturer-direct programs or your insurance.
Do I need a prescription, and can MEDVi guarantee I'll get one?
Yes, a prescription is required, and no, it is not guaranteed. A licensed provider must evaluate your information and determine whether a GLP-1 medication is appropriate for you; people with certain contraindications won't be eligible. There is no legitimate way to obtain these medications without a consultation and prescription, and any service implying otherwise should be avoided.
How much weight will I lose on MEDVi?
We can't tell you that, and neither can any telehealth provider. Published trials of the FDA-approved branded drugs reported substantial average reductions — roughly 14.9% over 68 weeks for branded semaglutide 2.4 mg in the STEP 1 trial, and up to about 20.9% over 72 weeks for tirzepatide at the highest dose in SURMOUNT-1 — but those are study averages for the branded formulations under trial conditions, not predictions for you or claims about any compounded product. Individual outcomes depend on your clinician's plan, your physiology, dose, and adherence.
How does MEDVi compare to Henry Meds, Eden, or Ivim Health?
They're broadly similar: most are cash-pay telehealth services built around compounded semaglutide and tirzepatide, and the real differences are smaller than the marketing implies. MEDVi differentiates on its flat bundled-membership pricing and included supervision; Ivim leans more lab-and-coaching forward; Eden publishes dose-tiered pricing; Henry Meds is one of the better-known early entrants. If FDA-approved medication matters most to you, manufacturer-direct options like LillyDirect and NovoCare are a different category worth comparing against all of them.
Is this article medical advice?
No. This is an independent, educational editorial review for adults 18 and older. It is not medical advice and not a substitute for consultation with a licensed healthcare provider. We are not paid for placement, prices are provider-attributed and change (verify at the source), and any GLP-1 prescription requires evaluation by a licensed clinician. Compounded medications referenced here are not FDA-approved.
Filed under Review